Positive feedback loop involving AMPK and CLYBL acetylation links metabolic rewiring and inflammatory responses.

Summary

The study identifies an AMPK–CLYBL acetylation positive feedback loop that drives inflammatory macrophage metabolism and cytokine release, with SIRT2 as a key mediator. Inhibition of CLYBL K154 acetylation reduced monocyte infiltration and attenuated cardiac remodeling, highlighting a therapeutic immunometabolic target.

Key Findings

• CLYBL K154 acetylation is required for inflammatory macrophage metabolic reprogramming; blocking it restricts pro-inflammatory factor release.
• A TLR-triggered AMPK–CLYBL acetylation positive feedback loop (AMPK hypophosphorylation, CLYBL hyperacetylation) was identified, with SIRT2 bridging AMPK phosphorylation and CLYBL acetylation.
• CLYBL hypoacetylation reduced monocyte infiltration and alleviated cardiac remodeling in vivo.

Clinical Implications

While preclinical, targeting the AMPK–CLYBL–SIRT2 axis could modulate macrophage-driven inflammation and adverse remodeling in ischemic or inflammatory heart disease.

Limitations

• Preclinical study; human validation and safety/efficacy data are lacking
• Specificity and off-target effects of modulating CLYBL acetylation in complex tissues remain to be defined

Future Directions

Validate the AMPK–CLYBL–SIRT2 axis in human tissues; develop selective modulators of CLYBL acetylation; test therapeutic impact in ischemia-reperfusion and heart failure models.